Hsbc Holdings PLC Purchases 20,672 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Hsbc Holdings PLC grew its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 35.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,327 shares of the company’s stock after acquiring an additional 20,672 shares during the period. Hsbc Holdings PLC’s holdings in Health Catalyst were worth $479,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of HCAT. Primecap Management Co. CA increased its holdings in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares in the last quarter. Nepsis Inc. increased its stake in shares of Health Catalyst by 8.3% in the second quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock valued at $8,007,000 after buying an additional 95,686 shares in the last quarter. Kennedy Capital Management LLC bought a new position in shares of Health Catalyst in the first quarter valued at about $8,780,000. Acadian Asset Management LLC lifted its position in Health Catalyst by 1.3% during the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock worth $4,690,000 after buying an additional 9,697 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in Health Catalyst by 1.4% during the 2nd quarter. American Century Companies Inc. now owns 683,464 shares of the company’s stock worth $4,367,000 after acquiring an additional 9,466 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $8.05 on Wednesday. The firm has a 50 day moving average price of $7.43 and a 200 day moving average price of $6.89. The stock has a market cap of $475.23 million, a P/E ratio of -4.35 and a beta of 1.31. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.21) EPS. Analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The disclosure for this sale can be found here. Insiders have sold a total of 30,153 shares of company stock valued at $216,004 over the last 90 days. 2.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Evercore ISI reduced their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Piper Sandler dropped their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Friday, September 20th. Finally, Stephens lowered their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.42.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.